TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
SLGC

Somalogic Inc

Healthcare · Health Information Services

19.10$ -0.4% vs. previous close Closing price · As of: Aug 13, 2026

Ownership

Ownership Structure

Who owns Somalogic Inc (SLGC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 81.2% of the shares are freely tradable; institutional investors hold 61.7%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 61.7%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 2.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 81.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 4.2%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 189Mio.

Largest Shareholders

Funds

Funds SLGC
Name Stake (%) Shares Change (%) Date
ARK Genomic Revolution 7.48 14,114,625 +9.7 12/31/2023
Vanguard Total Stock Mkt Idx Inv 2.20 4,157,015 +0.0 12/31/2023
Morgan Stanley Inception 0.48 904,556 -6.5 12/31/2023
Morgan Stanley Inst Inception I 0.48 904,556 -3.9 12/31/2023
Fidelity Extended Market Index 0.46 871,985 -4.4 12/31/2023
NT R2000 Value Index Fund - NL 0.23 437,404 +0.0 12/31/2023
EQ/Morgan Stanley Small Cap Growth K 0.22 414,837 +0.0 12/31/2023
BlackRock Extended Mkt Composite 0.20 380,070 +0.7 09/30/2023
BlackRock Extended Equity Market K 0.17 327,686 -0.2 12/31/2023
Fidelity Total Market Index 0.16 294,420 +0.0 12/31/2023

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?